RoyMunson69 Posted - 2 hours ago

$SPRY Men can’t carry it in their pockets. Just a total failed concept.

Pranee2023 Posted - 23 hours ago

$SPRY only one pharmacy to send prescriptions. A lot of coverage denials.

TheGodsMustBeCrazy Posted - 1 day ago

I agree with @rahmanoof $ALDX could easily get approved in early Feb or even late January, ie months early. $SPRY recently had that experience. They resubmitted their NDA 4-3-2024; were given a PDUFA date that was 6-months post resubmission; but FDA ended up approving them a full TWO MONTHS EARLY. Reason being: FDA team has already reviewed 95% of the NDA (from the first submission review period). Same goes for $ALDX: the FDA team has already reviewed 95% of ALDX's NDA already. Moreover, FDA's CRL said that only deficiency was 1 SINGLE STUDY, &then fda review team THEMSELVES designed the required study for ALDX to conduct to satisfy the CRL. So fda review team can review the new study in a week. This is a classic case where approval is likely to occur MONTHS before the pdufa.People forget this bc people are used to a 1st-round submission where fda almost always takes the full review time allowance. Not so with resubmissions.Ergo: odds of ALDX approval signif before pdufa are VERY high.

TheGodsMustBeCrazy Posted - 1 day ago

@jaxon613 you said $SPRY was approved 6 months after they resubmitted their NDA. That's false. They were approved ~4 months after the resubmitted their NDA.

TheGodsMustBeCrazy Posted - 1 day ago

@jaxon613 "It's 6 months, like it is supposed to be- I guess what I am saying is that , that is nothing more special then normal" Nah. What you're saying is not true. $SPRY's resubmitted their NDA, were given a PDUFA date that was 6 months post-resubmission, but FDA ended-up approving the NDA after only ~4 months post resubmission. Which means: FDA sometimes approves a resubmitted nda SIGNIFICANTLY EARLIER than pdufa date. Reason being: the fda review team has already pored over the bulk the NDA materials in-depth during the first submission review period, so they frequently don't need the full 6 months to review the new material. Therefore: $ALDX's NDA could easily get approved MONTHS BEFORE their pdufa of April 2, 2024. we could get a surprise early approval in January or February. After all, the FDA review team were the ones who designed the recent ALDX study which won (p=0.004), so reviewing it should take like 5 nanoseconds.

rahmanoof Posted - 1 day ago

$ALDX $spry received FDA approval after second NDA 2 months earlier than anticipated PDUFA date . Fruit for thought

prototyper Posted - 1 day ago

@ClearCities I've been noticing $SPRY volume drop considerably and our volume continuously increasing.

nomas Posted - 2 days ago

$SPRY apparently also has off label use for anal constriction - tight sphyncter - greenwich lockjaw - when properly administered. $AQST has not been mentioned for this off label use (yet).

ClarityOfPurpose Posted - 2 days ago

$SPRY Blood pressure drops rapidly during anaphylaxis. A larger initial increase in BP using neffy may actually be a good thing. Let the scientists figure it out. “While neffy effectively increases BP and HR with minimal interference from β2-mediated vasodilation or activation of compensatory mechanisms, it is important to note that there are PD ceilings.”

RoyMunson69 Posted - 2 days ago

$SPRY flooding the a1 receptors, ticking time bomb 💣💣💣💣💔

RoyMunson69 Posted - 2 days ago

$SPRY Big boys dumping

BiotechPsycho Posted - 2 days ago

$SPRY Ray James is upgrading their Q4 revenue estimate to 2.6M and then raising price target/market cap to 2.6 billion dollars? Where is the disconnect? A 2.6M revenue in a quarter equates to a 2.6B market cap? Total scam company. Invest in $AQST, a real company with a future.

RoyMunson69 Posted - 2 days ago

$SPRY Poor uptake because it’s dangerous? Owie owie owie

BioEmerging Posted - 2 days ago

$SPRY what royalty are we paying nuerelis?

Rangerbobtribute Posted - 5 days ago

$SPRY Hannah Glass a Wisconsin college student just died from an allergic reaction…epipen avoidance…she took Benadryl … she called her parents…delaying using epipen…epipen phobia is killing people.

prototyper Posted - 5 days ago

$AQST $SPRY i swear as soon as i saw this i thought it was neffy but its not. Life saving for opiods. (If it was i d have been kinda bullish on neffy LOL) Similar consuming method i assume. Expect to see 109 there

ClarityOfPurpose Posted - 6 days ago

$SPRY For those talking about the GCP-illegal idea that neffy should have been tested in induced anaphylaxis, just get over it. That wasn’t done for EpiPen either. If it would make these people feel better, just keep their EpiPen as their second (backup) epi.

Ohzipit Posted - 6 days ago

$SPRY RJ update page 2

Ohzipit Posted - 6 days ago

$SPRY RJ model update post earnings. Reiterating Strong Buy and price increase from$22 to $26. Page 1

BlackMyth Posted - 6 days ago

$AQST $SPRY What is the incentive for a doctor to prescribe this drug which has not been tested on real patients; especially under distress situation? Doctors know EpiPen is a sure bet, and they have good relationship with Viatris for decades.

ClarityOfPurpose Posted - 6 days ago

$SPRY I want to see great revenue but this may be an important side issue for health authorities to watch out for, regarding the potential abuse through use of a convenient nasal spray. I think an epi film would be even more problematic in this regard. https://www.mywowhealth.com/the-rise-of-epinephrine-a-new-drug-abuse-trend-sweeping-the-nation/

ClarityOfPurpose Posted - 6 days ago

$SPRY Double your pleasure, double your fun. Double the sales😉. From neffy.com: “Always carry two neffy nasal sprays with you because you may not know when anaphylaxis may happen and because you may need a second dose of neffy if symptoms continue or come back”.

IN0V8 Posted - 1 week ago

$SPRY Watch / Opportunity Leerink Partners raises target price to $26 from $25

Cash_loot Posted - 1 week ago

$AQST After seeing the devastation of the pps of $SPRY, $AQST will be DECIMATED. Spry selling massively and will show next quarter. AQST won't even get Euro approvals. Fully expect the plunge into the 3's area. Drs won't prescribe this flawed application.

SHADOWxGAINZ Posted - 1 week ago

$AQST $SPRY

BlackMyth Posted - 1 week ago

$AQST $SPRY Congrats AQST investors, SPRY finally crashed. We should see SPRY under $10 in near future. Doctors are not stupid enough to let their patients be the guinea pig for a drug that has not been tested on real patients. Doctors are vulnerable to lawsuits if something bad happen to the patient. therefore, doctors are not willing to prescribe Neffy. Doctors will continue to prescribe EpiPen to protect them from lawsuits.

ClarityOfPurpose Posted - 1 week ago

$SPRY You know that your kid would take the competing film product off the back of their phone before doing a mirror selfie.🪞🤳And some of the kids won’t even want others to see it attached to their phone in the first place. Maybe they would just store it somewhere else, like next to their other stash ;-). Just get a neffy instead!

ClarityOfPurpose Posted - 1 week ago

$SPRY Don’t you think the $145M up front from ALK is a significant vote of confidence. They know their potential market in Europe better than we do.

SHADOWxGAINZ Posted - 1 week ago

$SPRY options expiry this Friday. Calls look heavy on $17.5, take that how you will.

Fireflyaway Posted - 1 week ago

$SPRY Took a loss in SPRY to invest in $AQST much better value right now.